Jove
Visualize
Contact Us

Related Concept Videos

Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

928
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
928
Immune Response Against Viral Pathogens01:29

Immune Response Against Viral Pathogens

795
The immune system's response to viral infections is a complex and coordinated process involving natural killer (NK) cells, T cell-mediated responses, and antibody-mediated responses.
NK Cells
NK cells are a crucial part of our innate immune system, acting as the first line of defense against viral infections. These cells can recognize and kill infected cells without prior exposure to the virus, effectively slowing down the spread of infection. Additionally, NK cells produce proinflammatory...
795
Cell-mediated Immune Responses01:40

Cell-mediated Immune Responses

68.6K
Overview
68.6K
T Cell Types and Functions01:24

T Cell Types and Functions

1.0K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Challenges and future directions for multiple sclerosis after the 2024 McDonald diagnostic criteria.

Nature medicine·2026
Same author

Sex-specific analysis of early disease course and treatment in a German multiple sclerosis cohort.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same author

A CSF disease-associated macrophage signature defines progressive multiple sclerosis.

Journal of neuroinflammation·2026
Same author

Emerging CSF and Serum Biomarkers in Multiple Sclerosis: Cytokines, MOG, GFAP, and Beyond.

Neurology(R) neuroimmunology & neuroinflammation·2026
Same author

Treatment-free remission in MS: long-term disease control with cladribine tablets.

Journal of neurology·2026
Same author

Confined B-Cell Reconstruction and High T-Cell Clonality Define Clinical Response to Cladribine Treatment.

Annals of neurology·2026
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jul 11, 2025

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

12.3K

Learning CNS immunopathology from therapeutic interventions.

Nicholas Schwab1, Heinz Wiendl1,2

  • 1Department of Neurology with Institute of Translational Neurology, University of Muenster, Muenster 48149, Germany.

Science Translational Medicine
|November 8, 2023
PubMed
Summary

Targeting immune cell movement across the blood-brain barrier offers new therapies for multiple sclerosis (MS). Clinical trial data and patient studies enhance understanding of CNS immune responses in MS.

More Related Videos

Isolating Central Nervous System Tissues and Associated Meninges for the Downstream Analysis of Immune cells
09:35

Isolating Central Nervous System Tissues and Associated Meninges for the Downstream Analysis of Immune cells

Published on: May 19, 2020

9.4K
Simultaneous Isolation of Principal Central Nervous System-Resident Cell Types from Adult Autoimmune Encephalomyelitis Mice
08:49

Simultaneous Isolation of Principal Central Nervous System-Resident Cell Types from Adult Autoimmune Encephalomyelitis Mice

Published on: October 6, 2023

1.7K

Related Experiment Videos

Last Updated: Jul 11, 2025

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

12.3K
Isolating Central Nervous System Tissues and Associated Meninges for the Downstream Analysis of Immune cells
09:35

Isolating Central Nervous System Tissues and Associated Meninges for the Downstream Analysis of Immune cells

Published on: May 19, 2020

9.4K
Simultaneous Isolation of Principal Central Nervous System-Resident Cell Types from Adult Autoimmune Encephalomyelitis Mice
08:49

Simultaneous Isolation of Principal Central Nervous System-Resident Cell Types from Adult Autoimmune Encephalomyelitis Mice

Published on: October 6, 2023

1.7K

Area of Science:

  • Neuroimmunology
  • Translational Medicine
  • Central Nervous System (CNS) Research

Background:

  • Multiple sclerosis (MS) involves complex immune cell interactions within the CNS.
  • Understanding immune cell trafficking across the blood-brain barrier is crucial for MS.
  • Reverse translational medicine, using clinical data to inform basic science, is key.

Purpose of the Study:

  • To discuss how modulating immune cell trafficking impacts MS therapeutics.
  • To analyze data from natalizumab and fingolimod clinical trials.
  • To explore how patient biomaterial studies inform CNS immunopathology understanding.

Main Methods:

  • Review of clinical trial data for MS therapies (natalizumab, fingolimod).
  • Analysis of patient biomaterial-based scientific projects.
  • Integration of findings to understand CNS immune surveillance and immunopathology.

Main Results:

  • Clinical trials revealed distinct immune cell compartment involvement in relapsing vs. non-relapsing MS.
  • Therapeutic modulation of blood-brain barrier trafficking offers a viable MS treatment strategy.
  • Research has stimulated new avenues for investigating CNS immune biology.

Conclusions:

  • Modulating immune cell trafficking is a promising therapeutic approach for MS.
  • Clinical trials and patient studies significantly advance our knowledge of CNS immunopathology.
  • Reverse translational medicine is vital for understanding and treating MS.